JP2014528453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528453A5 JP2014528453A5 JP2014534755A JP2014534755A JP2014528453A5 JP 2014528453 A5 JP2014528453 A5 JP 2014528453A5 JP 2014534755 A JP2014534755 A JP 2014534755A JP 2014534755 A JP2014534755 A JP 2014534755A JP 2014528453 A5 JP2014528453 A5 JP 2014528453A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ras
- antagonist according
- ras antagonist
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 16
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 230000003211 malignant effect Effects 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 230000004663 cell proliferation Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 3
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000037816 tissue injury Diseases 0.000 claims 2
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims 1
- VBXZSFNZVNDOPB-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrimidine Chemical compound C1CNC=NC1 VBXZSFNZVNDOPB-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- -1 di-substituted amino Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544471P | 2011-10-07 | 2011-10-07 | |
| US61/544,471 | 2011-10-07 | ||
| PCT/US2012/058900 WO2013052765A1 (en) | 2011-10-07 | 2012-10-05 | Malignant and non-malignant disease treatment with ras antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528453A JP2014528453A (ja) | 2014-10-27 |
| JP2014528453A5 true JP2014528453A5 (https=) | 2015-11-26 |
| JP6165744B2 JP6165744B2 (ja) | 2017-07-19 |
Family
ID=48044179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534755A Expired - Fee Related JP6165744B2 (ja) | 2011-10-07 | 2012-10-05 | Ｒａｓアンタゴニストによる悪性および非悪性疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9309203B2 (https=) |
| EP (1) | EP2763681B1 (https=) |
| JP (1) | JP6165744B2 (https=) |
| CN (1) | CN103906518B (https=) |
| AU (1) | AU2012318471B9 (https=) |
| CA (1) | CA2849421C (https=) |
| ES (1) | ES2642843T3 (https=) |
| IL (1) | IL231757A (https=) |
| MX (1) | MX364551B (https=) |
| RU (1) | RU2632097C2 (https=) |
| WO (1) | WO2013052765A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9738614B2 (en) * | 2011-10-07 | 2017-08-22 | Pisces Therapeutics, Llc | Malignant and non-malignant disease treatment with Ras antagonists |
| CN103304501B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一类抗糖尿病化合物、其制备方法和用途 |
| CN103304503B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 抗糖尿病化合物、其制备方法和用途 |
| CN103304500B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 新型抗糖尿病化合物、其制备方法和用途 |
| CN103304498B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一种抗糖尿病化合物、其制备方法和用途 |
| CN103304499B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 抗糖尿病化合物、其制备方法和用途 |
| US10407734B2 (en) | 2013-11-18 | 2019-09-10 | Yale University | Compositions and methods of using transposons |
| WO2016056606A1 (ja) * | 2014-10-07 | 2016-04-14 | 国立大学法人京都大学 | ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品 |
| EP3417866B1 (en) | 2016-02-16 | 2020-12-23 | Osaka University | Medicinal composition for treating fibrosis |
| TR201920922A2 (tr) * | 2019-12-20 | 2020-06-22 | Ankara Ueniversitesi | 3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107587A (en) | 1993-11-12 | 1998-08-16 | Univ Ramot | Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation |
| WO1998017629A1 (en) * | 1996-10-24 | 1998-04-30 | Kyowa Hakko Kogyo Co., Ltd. | 1,4-benzoquinone derivatives |
| CA2280752A1 (en) | 1997-02-26 | 1998-09-03 | Ariella Paz | Drug screen targeting lipoprotein-membrane anchorage |
| KR100708360B1 (ko) * | 1999-01-21 | 2007-04-17 | 브리스톨-마이어스스퀴브컴파니 | 라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법 |
| US6462086B1 (en) * | 1999-06-18 | 2002-10-08 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Non-malignant disease treatment with Ras antagonists |
| US20020115696A1 (en) * | 1999-06-18 | 2002-08-22 | Yoel Kloog | Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists |
| US20050119237A1 (en) | 1999-06-18 | 2005-06-02 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Non-malignant disease treatment with Ras antagonists |
| WO2004103352A1 (en) | 2003-05-23 | 2004-12-02 | Ramot At Tel Aviv University, Ltd. | Ras antagonists for treating neurodegenerative disorders |
| EP2301528B1 (en) * | 2004-08-18 | 2013-04-03 | Kadmon Corporation, LLC | Use of FTS for treating malignant disorders |
| WO2007064448A2 (en) | 2005-11-28 | 2007-06-07 | Ramot At Tel Aviv University, Ltd. | Cancer treatment using fts and 2-deoxyglucose |
| WO2007091241A1 (en) | 2006-02-10 | 2007-08-16 | Ramot At Tel Aviv University Ltd. | Treatment of ovarian cancer |
| WO2007116396A1 (en) | 2006-04-11 | 2007-10-18 | Ramot At Tel Aviv University Ltd. | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor |
| WO2007144889A2 (en) | 2006-06-14 | 2007-12-21 | Ramot At Tel Aviv University Ltd. | Treatment of neurofibromatosis |
| EP2094260B1 (en) | 2006-12-19 | 2012-02-01 | Ramot at Tel-Aviv University Ltd. | Treatment of lung cancer |
| WO2009048541A2 (en) * | 2007-10-05 | 2009-04-16 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
-
2012
- 2012-10-05 ES ES12838578.8T patent/ES2642843T3/es active Active
- 2012-10-05 EP EP12838578.8A patent/EP2763681B1/en not_active Not-in-force
- 2012-10-05 CA CA2849421A patent/CA2849421C/en not_active Expired - Fee Related
- 2012-10-05 CN CN201280048941.1A patent/CN103906518B/zh not_active Expired - Fee Related
- 2012-10-05 WO PCT/US2012/058900 patent/WO2013052765A1/en not_active Ceased
- 2012-10-05 MX MX2014004126A patent/MX364551B/es active IP Right Grant
- 2012-10-05 US US14/350,303 patent/US9309203B2/en not_active Expired - Fee Related
- 2012-10-05 RU RU2014118430A patent/RU2632097C2/ru active
- 2012-10-05 JP JP2014534755A patent/JP6165744B2/ja not_active Expired - Fee Related
- 2012-10-05 AU AU2012318471A patent/AU2012318471B9/en not_active Ceased
-
2014
- 2014-03-27 IL IL231757A patent/IL231757A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528453A5 (https=) | ||
| RU2014118430A (ru) | Лечение злокачественных и незлокачественных заболеваний с помощью антагонистов ras | |
| KR102246652B1 (ko) | 암 치료용 화합물 | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| Burbuliene et al. | Synthesis and anti-inflammatory activity of derivatives of 5-[(2-disubstitutedamino-6-methyl-pyrimidin-4-yl)-sulfanylmethyl]-3H-1, 3, 4-oxadiazole-2-thiones | |
| RU2015132105A (ru) | Азоловые производные бензола | |
| JP2016536363A5 (https=) | ||
| ES2314418T3 (es) | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. | |
| RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
| JP2016536364A5 (https=) | ||
| JP2017500321A5 (https=) | ||
| JP2004175807A5 (https=) | ||
| JP2004532234A (ja) | トリアゾール由来キナーゼインヒビターおよびその使用 | |
| PE20110570A1 (es) | Heterociclos biciclicos sustituidos | |
| JP2009534386A5 (https=) | ||
| EA026674B1 (ru) | Соединения, применимые в качестве лекарственных средств | |
| RU2015101115A (ru) | Гетероароматическое циклическое производное с алкильной разветвленной цепью | |
| JP2010524937A5 (https=) | ||
| KR920008017A (ko) | 피페라진 유도체 | |
| Kavitha et al. | Biological aspects of 1, 3, 4-oxadiazole derivatives | |
| JP2015536974A5 (https=) | ||
| NZ603777A (en) | Bicyclic compound derivatives and their use as acc inhibitors. | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| RU2011137324A (ru) | Лиганды рецепторов эстрогенов и способы их применения |